MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Frequently asked questions
What sector does MeiraGTx Holdings plc (MGTX) operate in?
MeiraGTx Holdings plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is MeiraGTx Holdings plc (MGTX) current stock price?
As of the latest data, MeiraGTx Holdings plc stock price is $9.43, with a previous close of $9.18. MeiraGTx Holdings plc gained $0.25 in the last trading session, representing a 2.67% increase.
What is MeiraGTx Holdings plc (MGTX) current market capitalization?
MeiraGTx Holdings plc market cap is approximately 905.21 million.
What is MeiraGTx Holdings plc (MGTX) Earnings Per Share (EPS)?
The trailing EPS is $0.89, and the forward EPS is -$1.39.
What is MeiraGTx Holdings plc (MGTX) Price-to-Earnings (P/E) ratio?
MeiraGTx Holdings plc current P/E ratio is 10.59.
What is MeiraGTx Holdings plc (MGTX) EBITDA?
MeiraGTx Holdings plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 323.02 million.
Does MeiraGTx Holdings plc (MGTX) pay dividends?
No. MeiraGTx Holdings plc does not pay a dividend.
How did MeiraGTx Holdings plc (MGTX) perform in its most recent earnings report?
In the last report (June 30, 2026), MeiraGTx Holdings plc posted an EPS surprise of 538.46% and a revenue surprise of 2,977.12%.
What is MeiraGTx Holdings plc (MGTX) beta (volatility) score?
MeiraGTx Holdings plc has a beta of 1.273, suggesting it is more volatile than the market.
